BiotechTube

TNX-103 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Hypertension

Conditions

Pulmonary Hypertension

Trial Timeline

Jan 10, 2024 → Oct 1, 2028

NCT ID
NCT05983250

About TNX-103 + Placebo

TNX-103 + Placebo is a phase 3 stage product being developed by Medpace for Pulmonary Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05983250. Target conditions include Pulmonary Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05983250Phase 3Recruiting

Competing Products

20 competing products in Pulmonary Hypertension

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
44
macitentan 10 mgBML, Inc.Phase 3
76
tadalafil + tadalafilEli LillyPhase 3
77
CS1 AdministrationCereno ScientificPhase 2
47
CS1Cereno ScientificPre-clinical
18
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
52
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
41
DS-9231 + PlaceboDaiichi SankyoPhase 2
52
RegadenosonAstellas PharmaPre-clinical
23
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
MonteplaseEisaiApproved
85
lysozyme 90 mg + PlaceboEisaiApproved
85
Prednisolone + VoriconazoleCiplaPhase 2/3
65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
52
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
85

Other Products from Medpace

Lesinurad + XOI + Placebo + colchicine + corticosteroidsApproved
82
VI-0521 + VI-0521 + Placebo matched phentermine/topiramatePhase 3
74
lerodalcibepPhase 3
74
lerodalcibepPhase 3
74
Flutemetamol (18F) InjectionPhase 3
74